ADALYA's work included performing due diligence regarding a pharmaceutical company for a client considering its purchase and putting together a financing package for the deal.
We carried out an analysis of the activities of the potential buyer and the target company to evaluate the potential synergy benefits of the proposed deal and its commercial risks. The financing needs of the target company and the securities of the potential buyer were also evaluated for the formulation of a complete financing package, including the financing of the purchase and of the activities of the target company.
A financial forecast evaluating the repayment abilities of the target company was also drawn up. It estimated the dividend the buyer would be expected to draw, which was intended as the main source for paying back the debt accrued for the purchase.
A final recommendation about the profitability of the deal was made, including its commercial risks and the possible loss of synergy from the merger of the pharmaceutical activities of the potential buyer and the target company. Funding for the deal and for the financing of the activities of the target company was also raised.
Our analysis contributed significantly to the eventual execution of the deal.